Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 49706-2103; 59285-010; 66039-871; 31722-030; 43598-852; 45963-454; 45963-456; 67877-552; 69238-1703; 69452-161; 69539-200; 70700-271; 70771-1410; 70771-1471; 58032-2017; 0078-0468; 0078-0469; 31722-013; 43598-854; 69238-1488; 69452-159; 69539-023; 46708-410; 57664-768; 62332-324; 62756-568; 69539-021; 69539-073; 69539-199; 62332-412; 67877-550; 67877-553; 69097-391; 69097-560; 69539-022; 70771-1472; 65727-037; 0078-0655; 42806-371; 43598-851; 67877-554; 68462-495; 68462-496; 69097-392; 70710-1012; 62512-0078; 0078-0470; 0078-0654; 0078-0720; 31722-029; 43598-856; 46708-411; 46708-412; 69097-393; 69238-1486; 69539-303; 70710-1276; 72205-176; 14501-0049; 63278-1070; 65085-0063; 66022-0301; 0078-0656; 31722-031; 43598-855; 57664-769; 62332-325; 62756-569; 69539-075; 70710-1011; 72205-075; 72647-372; 74436-0323; 31722-012; 43598-853; 62332-326; 62332-411; 62756-570; 68462-494; 69097-570; 69238-1487; 69238-1702; 69238-1704; 70710-1013; 70771-1411; 70771-1473; 0591-3853; 72647-371; 0591-2961; 11722-040; 53104-7713; 59651-419; 0078-0727; 42806-372; 46708-324; 46708-325; 57664-770; 67877-549; 69539-074; 70700-270; 72205-076; 65015-738; 0078-0713; 31722-011; 42806-373; 45963-455; 46708-326; 62332-410; 67877-551; 69097-550; 69452-160; 70700-269; 70710-1275; 70710-1277; 70771-1409; 72647-373; 65372-1164
UNII V8G4MOF2V9
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tendon pain15.07.01.0090.001239%Not Available
Liver injury12.01.17.012; 09.01.07.0220.009541%Not Available
Cytotoxic oedema17.07.02.0060.001859%Not Available
Hyperammonaemic encephalopathy17.13.01.005; 14.10.01.0060.001859%Not Available
Myelodysplastic syndrome transformation16.01.04.005; 01.10.04.0050.009913%Not Available
Gastrointestinal sounds abnormal07.01.01.0020.001239%Not Available
Hypertransaminasaemia09.01.02.0050.004585%Not Available
Anorectal discomfort07.03.03.0030.002726%Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.0160.014002%
Acute kidney injury20.01.03.0160.027261%
Gastrointestinal tract irritation07.08.03.0080.011152%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.001859%
Functional gastrointestinal disorder07.11.01.0160.002726%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
Hepatic cancer16.07.02.004; 09.04.02.0080.004337%Not Available
Autoimmune haemolytic anaemia01.06.01.004; 10.04.01.0050.001859%Not Available
Faeces soft07.01.03.008--Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.004213%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.012391%
Abnormal loss of weight14.03.02.0190.002726%Not Available
Brain neoplasm malignant17.20.04.002; 16.30.04.0020.001239%Not Available
Chronic gastritis11.07.01.016; 10.04.04.011; 07.08.02.0050.001239%Not Available
Concomitant disease aggravated08.01.03.0630.006815%Not Available
Coombs negative haemolytic anaemia01.06.03.0010.001239%Not Available
Haemosiderosis14.13.03.004; 12.02.08.0070.004956%Not Available
Moyamoya disease24.01.04.016; 17.08.02.0230.001859%Not Available
Normal newborn18.08.06.0010.001859%Not Available
Urinary bladder haemorrhage24.07.01.086; 20.03.01.0230.001239%Not Available
Kidney enlargement20.01.06.0030.001859%Not Available
Concomitant disease progression08.01.03.0640.003717%Not Available
The 16th Page    First    Pre   16 17 18    Next   Last    Total 18 Pages